Chinese Urologists’ Views of Practice Patterns in the Diagnosis and Treatment of Benign Prostatic Hyperplasia: A Nationwide Survey
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To assess the compliance of Chinese urologists with China’s benign prostatic hyperplasia (BPH) clinical practice guideline and to explore the diagnosis and therapy modalities for geriatric patients with BPH. Methods: A cross-sectional survey study was carried out in 33 medical centers in 11 different cities in China. A total of 190 urologists participated in a survey to record their preferences for diagnostic tests and treatment options for BPH outpatients. Diagnostic test results as well as health care demands were collected by surveying 2,027 outpatients aged 60 years and older. Results: The survey response rate was 97.4%. The respondents generally used the diagnostic tests recommended in China’s BPH clinical practice guideline at varying rates. The used rates for medical history, ultrasonography, and urinalysis were above 90.0%; that for uroflowmetry was 31.2%. In addition, the rate of use of recommended tests was higher among doctors in the north than among those in the south. Combination therapy with α-adrenoceptor antagonists and 5α-reductase inhibitors was the preferred treatment option for BPH, and was increasingly used with worsening lower urinary tract symptoms. Finasteride was the most prescribed medication (48.0%), followed by tamsulosin (22.7%). Conclusions: This study assessed the preferences of urologists in the diagnosis and treatment of BPH, which will serve as an important reference for updating and improving China’s current BPH clinical practice guideline.
Abstract
Purpose: To assess the compliance of Chinese urologists with China’s benign prostatic hyperplasia (BPH) clinical practice guideline and to explore the diagnosis and therapy modalities for geriatric patients with BPH. Methods: A cross-sectional survey study was carried out in 33 medical centers in 11 different cities in China. A total of 190 urologists participated in a survey to record their preferences for diagnostic tests and treatment options for BPH outpatients. Diagnostic test results as well as health care demands were collected by surveying 2,027 outpatients aged 60 years and older. Results: The survey response rate was 97.4%. The respondents generally used the diagnostic tests recommended in China’s BPH clinical practice guideline at varying rates. The used rates for medical history, ultrasonography, and urinalysis were above 90.0%; that for uroflowmetry was 31.2%. In addition, the rate of use of recommended tests was higher among doctors in the north than among those in the south. Combination therapy with α-adrenoceptor antagonists and 5α-reductase inhibitors was the preferred treatment option for BPH, and was increasingly used with worsening lower urinary tract symptoms. Finasteride was the most prescribed medication (48.0%), followed by tamsulosin (22.7%). Conclusions: This study assessed the preferences of urologists in the diagnosis and treatment of BPH, which will serve as an important reference for updating and improving China’s current BPH clinical practice guideline.
참고문헌 (22)
- Roehrborn CG, "Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia, In Campbell’s urology. 8th ed", pp.1297~1336 (2002), WB Saunders
- Berry SJ, "The development of human benign prostatic hyperplasia with age", J Urol, 132, pp.474~479 (1984)
- Gu FL, "Preliminary study of the frequency of benign prostatic hyperplasia and prostatic cancer in China", Urology, 44, pp.688~691 (1994)
- Wei JT, "Urologic diseases in America project: benign prostatic hyperplasia", J Urol, 173, pp.1256~1261 (2005)
- McConnell JD, "Benign prostatic hyperplasia: diagnosis and treatment (Clinical practice guideline no. 8; AHCPR publication no. 94-0582)", U.S. Department of Health and Human Services, Agency for Healthcare Research and Quality, ~ (1994)
- Sagnier PP, "International comparison of the community prevalence of symptoms of prostatism in four countries", Eur Urol, 29, pp.15~20 (1996)
- Yu P, "Prevalence of prostatic hyperplasia and its relative factors in six cities of China in 1997", Zhonghua Liu Xing Bing Xue Za Zhi, 21, pp.276~279 (2000)
- Gravas S, "Translation of benign prostatic hyperplasia guidelines into clinical practice", Curr Opin Urol, 18, pp.56~60 (2008)
- Irani J, "A review of guidelines on benign prostatic hyperplasia and lower urinary tract symptoms: are all guidelines the same?", BJU Int, 92, pp.937~942 (2003)
- Kim HL, "Practice trends in the management of prostate disease by family practice physicians and general internists: an internet-based survey", Urology, 59, pp.266~271 (2002)
- Fukagai T, "Practice patterns regarding prostate cancer and benign prostatic hyperplasia in Japanese primary care practitioners", Int J Urol, 14, pp.412~415 (2007)
- Hutchison A, "Characteristics of patients presenting with LUTS", BPH in six European countries, 2006, pp.50, 555~561
- 백재승, "Patterns in the Diagnosis and Management of Benign Prostatic Hyperplasia in a Country that does not have Country-Specific Clinical Practice Guidelines", Yonsei Medical Journal, 48(2), pp.281~288 (2007), 연세대학교의과대학
- "Physicians’ desk reference. 61st ed" (2007), Thomson PDR
- Lin T, "Market analysis of medicines for treatment of benign prostatic hyperplasia in sample hospitals of Shanghai", Pharm Care Res, 6, pp.370~372 (2006)
- Bruskewitz R, "Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study", Urology, 54, pp.670~678 (1999)
- Kaplan SA, "Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial", J Urol, 185, pp.1369~1373 (2011)
- Vickers AJ, "Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated?", J Clin Oncol, 28, pp.1112~1116 (2010)
- Speakman MJ, "Integrating patient risk profiles in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS", BPH) in Clinical Practice, 2004, pp.3, 18~22
- McConnell JD, "The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia", N Engl J Med, 349, pp.2387~2398 (2003)
- Kaplan SA, "Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater", J Urol, 175, pp.217~220 (2006)
- 이지열, "Change in International Prostate Symptom Storage Subscore After Long-term Medical Therapy in BPH Patients: Finasteride and Alpha-blocker Combination Therapy in Men With Moderate-to-severe LUTS", BPH in Korea, 2011, pp.77(1), 171~176[DOI]